Get access

Fetal neural grafts for Huntington's disease: A prospective view

Authors

  • Anne-Catherine Bachoud-Lévi MD, PhD,

    1. Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil, France
    2. Department of Medical Neurosciences, CHU Henri-Mondor, 94010 Créteil France
    Search for more papers by this author
  • Philippe Hantraye PhD,

    1. CEA-CNRS URA 2210, Service Hospitalier Frédéric Joliot, 91401 Orsay Cedex, France
    Search for more papers by this author
  • Marc Peschanski MD, PhD

    Corresponding author
    1. Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil, France
    • INSERM U 421/IM3, Faculté de Médecine, 94010 Créteil France
    Search for more papers by this author

Abstract

Intrastriatal transplantation of striatal neuroblasts from human fetuses is a promising approach for treatment of Huntington's disease, on the basis of many experimental animal studies and, most recently, pilot clinical trials. Technically, several issues remain to be resolved (e.g., the precise site of dissection of the fetal tissue; the number and location of the fetal striatal implants; or the use of immunosuppressive therapy), and await larger-scale trials and purposely designed protocols. Further clinical data must also be obtained, and preliminary promising results must be replicated in a patient group large enough to provide conclusive results. It is important to establish (1) the amount of clinical benefit provided to the patient by the grafted cells; (2) the anticipated duration of clinical benefits; and (3) the secondary rate of decline after the benefit of the graft has been overbalanced. Evaluation of these parameters will require very long-term follow-up of the patients involved, over several years after grafting, before the technique can eventually be proposed widely to patients. © 2002 Movement Disorder Society

Ancillary